The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of multimodality therapy (MMT) in unresectable hilar cholangiocarcinoma (UHC).
N. A. Bhadkamkar
No relevant relationships to disclose
S. P. Kar
No relevant relationships to disclose
J. Weatherly
No relevant relationships to disclose
C. R. Garrett
No relevant relationships to disclose
J. Vauthey
No relevant relationships to disclose
A. O. Kaseb
No relevant relationships to disclose
P. Das
Research Funding - Genentech
M. M. Javle
No relevant relationships to disclose